Reader response: Blood NfL: A biomarker for disease severity and progression in Parkinson disease

被引:1
|
作者
van Rumund, Anouke
Marques, Taina M.
Esselink, Rianne A. J.
Bloem, Bastiaan R.
Verbeek, Marcel M.
机构
关键词
D O I
10.1212/WNL.0000000000010668
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
引用
收藏
页码:657 / 658
页数:2
相关论文
共 50 条
  • [21] Relationship between plasma NFL and disease progression in Parkinson’s disease: a prospective cohort study
    Ruwei Ou
    Kuncheng Liu
    Junyu Lin
    Tianmi Yang
    Yi Xiao
    Qianqian Wei
    Yanbing Hou
    Chunyu Li
    Lingyu Zhang
    Zheng Jiang
    Bi Zhao
    Xueping Chen
    Wei Song
    Ying Wu
    Huifang Shang
    Journal of Neurology, 2024, 271 : 1837 - 1843
  • [22] Relationship between plasma NFL and disease progression in Parkinson's disease: a prospective cohort study
    Ou, Ruwei
    Liu, Kuncheng
    Lin, Junyu
    Yang, Tianmi
    Xiao, Yi
    Wei, Qianqian
    Hou, Yanbing
    Li, Chunyu
    Zhang, Lingyu
    Jiang, Zheng
    Zhao, Bi
    Chen, Xueping
    Song, Wei
    Wu, Ying
    Shang, Huifang
    JOURNAL OF NEUROLOGY, 2024, 271 (04) : 1668 - 1679
  • [23] Response shift - The experience of disease progression in Parkinson disease
    Yang, Jessica
    Hanna-Pladdy, Brenda
    Gruber-Baldini, Ann L.
    Barr, Erik
    von Coelln, Rainer
    Armstrong, Melissa J.
    Reich, Stephen G.
    Shulman, Lisa M.
    PARKINSONISM & RELATED DISORDERS, 2017, 36 : 52 - 56
  • [24] GFAP and NfL as fluid biomarkers for clinical disease severity and disease progression in multiple system atrophy (MSA)
    Katzdobler, Sabrina
    Nuebling, Georg
    Klietz, Martin
    Fietzek, Urban M.
    Palleis, Carla
    Bernhardt, Alexander M.
    Wegner, Florian
    Huber, Meret
    Rogozinski, Sophia
    Schneider, Luisa-Sophie
    Spruth, Eike Jakob
    Beyle, Aline
    Vogt, Ina R.
    Brandt, Moritz
    Hansen, Niels
    Glanz, Wenzel
    Brockmann, Kathrin
    Spottke, Annika
    Hoffmann, Daniel C.
    Peters, Oliver
    Priller, Josef
    Wiltfang, Jens
    Duezel, Emrah
    Schneider, Anja
    Falkenburger, Bjoern
    Klockgether, Thomas
    Gasser, Thomas
    Nuscher, Brigitte
    Haass, Christian
    Hoeglinger, Guenter
    Levin, Johannes
    JOURNAL OF NEUROLOGY, 2024, : 6991 - 6999
  • [25] Plasma Cystatin C Correlates with Plasma NfL Levels and Predicts Disease Progression in Parkinson's Disease
    Imarisio, Alberto
    Pilotto, Andrea
    Garrafa, Emirena
    Conforti, Francesca
    Masciocchi, Stefano
    Turrone, Rosanna
    Gipponi, Stefano
    Cottini, Elisabetta
    Rizzetti, Maria Cristina
    Porrini, Vanessa
    Gussago, Cristina
    Pizzi, Marina
    Guadagni, Fiorella
    Zetterberg, Henrik
    Ashton, Nicholas J.
    Hye, Abdul
    Padovani, Alessandro
    NEURODEGENERATIVE DISEASES, 2022, 21 (5-6) : 109 - 116
  • [26] Effect of Aspartame on Parkinson's Disease Progression and Severity
    Kushigian, D.
    Vaou, O.
    MOVEMENT DISORDERS, 2022, 37 : S653 - S653
  • [27] Urinary angiostatin: a novel biomarker of kidney disease associated with disease severity and progression
    Yuan-Yuan Xia
    Ru Bu
    Guang-Yan Cai
    Xue-Guang Zhang
    Shu-Wei Duan
    Jie Wu
    Di Wu
    Xiang-Mei Chen
    BMC Nephrology, 20
  • [28] Urinary angiostatin: a novel biomarker of kidney disease associated with disease severity and progression
    Xia, Yuan-Yuan
    Bu, Ru
    Cai, Guang-Yan
    Zhang, Xue-Guang
    Duan, Shu-Wei
    Wu, Jie
    Wu, Di
    Chen, Xiang-Mei
    BMC NEPHROLOGY, 2019, 20 (1)
  • [29] Reader response: The nature of postural tremor in Parkinson disease
    Jankovic, Joseph
    NEUROLOGY, 2018, 91 (15) : 723 - 723
  • [30] Substantia Nigra Neuromelanin as an Imaging Biomarker of Disease Progression in Parkinson's Disease
    Fabbri, Margherita
    Reimao, Sofia
    Carvalho, Miguel
    Nunes, Rita G.
    Abreu, Daisy
    Guedes, Leonor Correia
    Bouca, Raquel
    Lobo, Patricia P.
    Godinho, Catarina
    Coelho, Miguel
    Goncalves, Nilza C.
    Rosa, Mario Miguel
    Antonini, Angelo
    Ferreira, Joaquim J.
    JOURNAL OF PARKINSONS DISEASE, 2017, 7 (03) : 491 - 501